Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective faithfully but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last several shares of mine. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire interview which I came away with a poor viewpoint of the business.

Irony of irony, the bad impression of mine of the business has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this technology as well as linked intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and also the first new drug program approval ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and numerous therapies, it has this individual remedy as well as a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

Its opening banner on the website of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, multiple illness types, multiple delivering presentations and multiple publications.

Could it all be smoke cigarettes and mirrors? That is a question I have been asking myself from the very beginning of the interest of mine in this business. Judging by the multiples of thousands of various remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a classic battleground, or some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *